Home Newsfeeds Needham Downgrades Viavi Solutions to Hold

Needham Downgrades Viavi Solutions to Hold

Needham analyst Alex Henderson downgrades Viavi Solutions (NASDAQ:VIAV) from Buy to Hold.

byBenzinga Newsdesk

July 19, 2022

1 minute read

Needham analyst Alex Henderson downgrades Viavi Solutions (NASDAQ:VIAV) from Buy to Hold.

Microsoft, Snap, Texas Instruments And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

By Lisa Levin

July 26, 6:40 AM

U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. Snap Inc. (NYSE: SNAP) shares tumbled 18.6% to $10.18 in pre-market trading after the company reported third-quarter results.

AURC

Datadog Analyst Highlights Growth Versus Public Cloud Providers And Cost Monitoring Versus Pandemic Times

By Anusuya Lahiri

November 7, 1:50 PM

Needham analyst Mike Cikos reiterated a Buy and $90 price target on Datadog, Inc (NASDAQ:DDOG) Since Datadog’s earnings release, client feedback has centered…

DDOG

Qualigen Therapeutics Announces Pre-IND Feedback From U.S. FDA Regarding QN-302 For The Treatment Of G4-Targeted Advanced Solid Tumors

By Benzinga Newsdesk

December 7, 10:11 AM

Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug

QLGN

News

RenaissanceRe Estimates Losses From Certain 2022 Catastrophe Events Will Have Net Negative Impact Of ~$650M On Co.’s Q3’22 Results Of Operations

By Michael Horton

October 19, 4:30 PM

RenaissanceRe Holdings Ltd. (NYSE:RNR) (the "Company" or "RenaissanceRe") today announced it estimates that losses from certain 2022 catastrophe events will have a net negative impact of

RNR

Needham Downgrades Viavi Solutions to Hold

Related Posts

Microsoft, Snap, Texas Instruments And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Datadog Analyst Highlights Growth Versus Public Cloud Providers And Cost Monitoring Versus Pandemic Times

Qualigen Therapeutics Announces Pre-IND Feedback From U.S. FDA Regarding QN-302 For The Treatment Of G4-Targeted Advanced Solid Tumors

RenaissanceRe Estimates Losses From Certain 2022 Catastrophe Events Will Have Net Negative Impact Of ~$650M On Co.’s Q3’22 Results Of Operations